IS2871B - Töflur sem innihalda 250 til 450 mg af módafíníli - Google Patents

Töflur sem innihalda 250 til 450 mg af módafíníli

Info

Publication number
IS2871B
IS2871B IS7714A IS7714A IS2871B IS 2871 B IS2871 B IS 2871B IS 7714 A IS7714 A IS 7714A IS 7714 A IS7714 A IS 7714A IS 2871 B IS2871 B IS 2871B
Authority
IS
Iceland
Prior art keywords
modafinil
tablets containing
tablets
Prior art date
Application number
IS7714A
Other languages
English (en)
Other versions
IS7714A (is
Inventor
Craig Heacock
Alpa Parikh
Piyush Patel
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32511269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2871(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of IS7714A publication Critical patent/IS7714A/is
Publication of IS2871B publication Critical patent/IS2871B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS7714A 2002-09-13 2005-02-24 Töflur sem innihalda 250 til 450 mg af módafíníli IS2871B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41039502P 2002-09-13 2002-09-13
US10/660,058 US20040116532A1 (en) 2002-09-13 2003-09-11 Pharmaceutical formulations of modafinil
PCT/US2003/028651 WO2004024134A1 (en) 2002-09-13 2003-09-12 Pharmaceutical formulations of modafinil

Publications (2)

Publication Number Publication Date
IS7714A IS7714A (is) 2005-02-24
IS2871B true IS2871B (is) 2014-03-15

Family

ID=32511269

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7714A IS2871B (is) 2002-09-13 2005-02-24 Töflur sem innihalda 250 til 450 mg af módafíníli

Country Status (21)

Country Link
US (4) US20040116532A1 (is)
EP (1) EP1539126B1 (is)
JP (1) JP5039246B2 (is)
KR (1) KR101125462B1 (is)
CN (1) CN100528151C (is)
AU (1) AU2003267156B2 (is)
BR (1) BR0314514A (is)
CA (1) CA2498260C (is)
DK (1) DK1539126T3 (is)
EA (1) EA012964B1 (is)
ES (1) ES2392580T3 (is)
IL (1) IL167054A (is)
IS (1) IS2871B (is)
MX (1) MXPA05002827A (is)
NO (1) NO333614B1 (is)
NZ (1) NZ538941A (is)
PL (1) PL375833A1 (is)
PT (1) PT1539126E (is)
SI (1) SI1539126T1 (is)
TW (1) TWI335217B (is)
WO (1) WO2004024134A1 (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20122504U1 (de) 2000-07-27 2005-12-29 Teva Pharmaceutical Industries Ltd. Kristallines und reines Modafinil
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
CN101031290B (zh) * 2003-09-18 2011-09-21 赛福伦公司 改良释放的莫达非尼药物组合物
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
MX2009001551A (es) * 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) * 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
UY31335A1 (es) * 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
FR2987265B1 (fr) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) 1923-11-20 1926-01-26 William A Cook Spring-forming die
US3629393A (en) 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
DE2927988A1 (de) 1979-07-11 1981-02-05 Thomae Gmbh Dr K Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel
US4431645A (en) 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4584285A (en) 1983-06-02 1986-04-22 Schering Corporation Antihypertensive agents
US4710519A (en) 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
TW272942B (is) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (is) * 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) * 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
ES2210490T3 (es) * 1996-01-19 2004-07-01 Glaxo Group Limited Uso de valaciclovir para la fabricacion de un medicamento para el tratamiento del herpes genital por una unica administracion diaria.
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
DE69740161D1 (de) 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
GB9714274D0 (en) 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
WO1999012524A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
HK1043043B (en) 1998-12-18 2004-09-10 Abbott Laboratories Controlled release formulation of sodium divalproex
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
CN1249932A (zh) * 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
JP4593074B2 (ja) * 2000-10-11 2010-12-08 セフアロン・インコーポレーテツド モダフィニル化合物含有組成物
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
HU229409B1 (en) 2000-10-11 2013-12-30 Cephalon Compositions comprising modafinil compounds
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
MXPA03010705A (es) 2001-05-25 2004-05-27 Cephalon Inc Formulaciones farmaceuticas solidas que comprenden modafinil.
US7576133B2 (en) * 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004004692A1 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20080044468A1 (en) 2002-07-25 2008-02-21 Romi Barat Singh Processes For The Preparation Of Oral Dosage Formulations Of Modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
HK1076734A1 (en) 2006-01-27
TW200412934A (en) 2004-08-01
EA012964B1 (ru) 2010-02-26
CN1681486A (zh) 2005-10-12
WO2004024134A1 (en) 2004-03-25
TWI335217B (en) 2011-01-01
WO2004024134A8 (en) 2005-07-21
US8859621B2 (en) 2014-10-14
ES2392580T3 (es) 2012-12-12
EP1539126A1 (en) 2005-06-15
AU2003267156A1 (en) 2004-04-30
NO20051079L (no) 2005-03-23
JP2006522006A (ja) 2006-09-28
JP5039246B2 (ja) 2012-10-03
IS7714A (is) 2005-02-24
US20080207761A1 (en) 2008-08-28
PT1539126E (pt) 2012-11-14
KR101125462B1 (ko) 2012-03-28
AU2003267156B2 (en) 2010-03-11
CA2498260A1 (en) 2004-03-25
US20040116532A1 (en) 2004-06-17
SI1539126T1 (sl) 2012-11-30
CN100528151C (zh) 2009-08-19
CA2498260C (en) 2014-02-04
PL375833A1 (en) 2005-12-12
NO333614B1 (no) 2013-07-22
IL167054A (en) 2011-07-31
EP1539126B1 (en) 2012-08-29
BR0314514A (pt) 2005-08-09
DK1539126T3 (da) 2012-11-19
KR20050113163A (ko) 2005-12-01
US8686047B2 (en) 2014-04-01
US20120316244A1 (en) 2012-12-13
US20120322880A1 (en) 2012-12-20
US8268892B2 (en) 2012-09-18
EA200500488A1 (ru) 2005-12-29
NZ538941A (en) 2007-09-28
MXPA05002827A (es) 2005-08-16

Similar Documents

Publication Publication Date Title
IS2871B (is) Töflur sem innihalda 250 til 450 mg af módafíníli
TWI347849B (en) Sustained-release tablet composition of pramipexole
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
ATE521334T1 (de) Schweisshemmende oder desodorierende zusammensetzung
IL163667A0 (en) Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
DK1524981T3 (da) Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
PT1458377E (pt) Composicoes farmaceuticas contendo tegaserod
ATE414705T1 (de) Entzündungshemmende di- und trifluortriazolopyridin-verbindungen
AU2003209439A1 (en) Non-steroidal analogs of 2-methoxyestradiol
DK1561472T3 (da) Faststofsammensætning
IS2616B (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
IL173738A0 (en) Modafinil modified release pharmaceutical compositions
IS6633A (is) Samsetningar af fínasteríð töflum
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
DE60326900D1 (de) Duftstoff-Zusammensetzung
EP1572950A4 (en) SINGLE-DOMAIN-TDF-RELATED CONNECTIONS AND ANALOGS OF IT
IL153098A0 (en) Pharmaceutical compositions containing modafinil
IS6857A (is) Lyfjafræðileg samsetning sem innheldur sítalópram
JP2005504877A5 (ja) 高レベルの特定アルコキシル化トリグリセリドを含む固形セッケン
AU2003217354A8 (en) Synthesis of sulfamidates
IS7821A (is) Lyfjatöflur sem innihalda tibólón og húðun
TW580005U (en) Structure of compound packing
PL356853A1 (en) Application of bacteriphages
SI1542666T1 (sl) Modafinil farmacevtski sestavki